Ton Adang
Corporate Officer/Principal at LAVA THERAPEUTICS N.V.
Net worth: 1 808 $ as of 2024-05-30
Ton Adang active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LAVA THERAPEUTICS N.V. | Corporate Officer/Principal | 2017-06-30 | - |
Career history of Ton Adang
Former positions of Ton Adang
| Companies | Position | Start | End |
|---|---|---|---|
EnCare Biotech BV
 EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Chief Operating Officer | 2014-07-31 | 2017-11-30 |
Fast Forward Pharmaceuticals BV
 Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Chief Operating Officer | 2012-09-30 | 2017-09-30 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Corporate Officer/Principal | 2014-07-31 | 2016-08-31 |
Simibio BV
 Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Chief Operating Officer | 2011-06-30 | 2014-05-31 |
| MERCK KGAA | Corporate Officer/Principal | 2009-10-31 | 2010-02-28 |
Training of Ton Adang
| University of Leiden | Doctorate Degree |
| Wageningen University | Graduate Degree |
Statistics
International
| Netherlands | 8 |
| Germany | 2 |
Operational
| Chief Operating Officer | 3 |
| Corporate Officer/Principal | 3 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 3 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| LAVA THERAPEUTICS N.V. | Health Technology |
| Private companies | 4 |
|---|---|
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
Fast Forward Pharmaceuticals BV
Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Health Technology |
Simibio BV
Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Health Technology |
EnCare Biotech BV
EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Health Services |
- Stock Market
- Insiders
- Ton Adang
- Experience
